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A B S T R A C T
Obstructive sleep apnea (OSA) commonly coexists with epilepsy, and treatment of OSA may decrease
seizure frequency. However, it is unclear whether patients with medically refractory epilepsy have a
higher incidence of OSA compared with well-controlled epilepsy patients and whether the two groups
carry different risk factors.
Purpose: This study aimed to investigate the presence of OSA in patients with refractory vs. well-
controlled epilepsy and their associated risk factors. We also assessed the beneﬁts of treatment of OSA
with continuous positive airway pressure (CPAP) in refractory epilepsy patients.
Methods: We retrospectively reviewed data from patients who presented to the Jacobs Neurological
Institute Comprehensive Epilepsy Center of University at Buffalo from 2007 to 2010.
Results: There is a tendency for much higher incidence of OSA in our epilepsy population compared with
the general population (15.2% vs. 4.41%). For patients with well-controlled epilepsy, older age, male
gender, and higher seizure frequency were predictors of a diagnosis of OSA. However, in medically
refractory epilepsy patients, diabetes and snoring predicted a diagnosis of OSA. Treatment of OSA with
CPAP in refractory epilepsy patients improved their seizure control (p < 0.02).
Conclusion: This study conﬁrms that OSA is common in epilepsy patients and treatment of OSA can
improve seizure control in medically refractory cases. Patients with refractory epilepsy who have
diabetes are more likely to have OSA.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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It is known that about 36% of epilepsy patients continue to have
seizures despite antiepileptic drugs (AEDs).1 Medically refractory
epilepsy is a major cause of disability leading to considerable
economic and social problems.2,3 The most effective way of
lowering the burden of epilepsy is by reducing the incidence of
recurrent seizures. Therefore, recognizing and treating modiﬁable
risk factors are of particular importance. It is well known that sleep
deprivation can activate epileptic activity as depicted during
electroencephalography (EEG) or occasionally cause seizures in
subjects without pre-existing epilepsy.4–9 Obstructive sleep apnea
(OSA) is one of the most common sleep-breathing disorders which
may exacerbate epilepsy by causing sleep disruption and
deprivation, hypoxemia, and decreased cerebral blood ﬂow.10* Corresponding author at: Department of Neurology, University of California,
Irvine, 101 The City Drive South, Bldg 30, 1st Floor, Rt. 29, Orange, CA 92868, USA.
Tel.: +1 714 456 6203; fax: +1 714 456 6908.
E-mail address: msazgar@uci.edu (M. Sazgar).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.07.016Studies have shown epilepsy patients have higher incidence of OSA
compared with the general population (10.2% vs. 4%).11 In addition,
in a previous study one third of epilepsy surgery candidates had
OSA and they were more likely to have seizures during sleep than
those without OSA.12 Therefore, it is not surprising that OSA
commonly coexists with epilepsy, and treatment of OSA may
decrease seizure frequency.13–16 Treatment with continuous
positive airway pressure (CPAP) has been associated with
improvement in seizure control.2,17,18 However, there are con-
ﬂicting data since Malow et al. showed no signiﬁcant difference in
seizure reduction in severely refractory epilepsy patients after
CPAP treatment compared with the sham CPAP group.19
Higher incidence of OSA has been shown in males,20 older
population,20,21 subjects with higher body mass index (BMI),20
hypertension,22 type 2 diabetes mellitus (DM),23 and with Epworth
Sleepiness Scale (ESS) score of 10 or greater.24 A limited number of
published studies have shown that epilepsy patients with OSA tend
to be of male gender, older, heavier, and sleepier than ‘‘epilepsy
only’’ patients.11,12 However, it is unclear whether patients with
refractory epilepsy have the same risk factors as patients with
well-controlled epilepsy.vier Ltd. All rights reserved.
Table 1
Characteristics of the patient population.
Well-controlled Refractory
Number 112 85
Age 44.8  16.6 42.0  15.1
Male 44 (39.3%) 34 (40.0%)
Age at seizure onset 27.6  22.2** 18.8  19.6**
BMI 27.0  5.7* 29.2  7.8*
Average number of AEDs 1.38  0.62*** 1.88  0.85***
Monotherapy 78 (69.6%)*** 31(36.5%)***
ESS 4.6  3.5 5.8  5.4
Snore 21 (18.8%) 21 (24.7%)
Difﬁculty falling sleep 20 (17.9)* 28 (32.9%)*
Difﬁculty staying sleep 33 (29.5%) 25 (29.4%)
Daytime sleepiness 16 (14.3%) 19 (22.4%)
Sleep disturbance 28 (25.0%) 34 (40.0%)*
Final seizure frequency 2.1  0.7*** 5.9  1.6***
HTN 19 (17.0%) 15 (17.7%)
DM 6 (5.4%) 8 (9.4%)
CHF 13 (11.6%) 12 (14.1%)
CAD 7 (6.3%) 7 (8.2%)
Stroke 6 (5.4%) 11 (12.6%)
OSA 17 (15.2%) 13 (15.3%)
Values reported are means  standard deviations, with corresponding percentages.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
BMI, body mass index; AED, antiepileptic drug; ESS, Epworth Sleepiness Scale; HTN,
hypertension; DM, diabetes mellitus; CHF, congestive heart failure; CAD, coronary
artery disease; OSA, obstructive sleep apnea.
Seizure frequency based on modiﬁed Engel Criteria.
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patients with medically refractory and well-controlled epilepsy as
related to risk factors for sleep apnea including sex, age, obesity,
hypertension, and DM and to determine the effects of CPAP
treatment on seizure control in medically refractory vs. well
controlled epilepsy population.
2. Materials and methods
We conducted a chart review retrospective study of the patients
presenting to the Comprehensive Epilepsy Center of the Jacobs
Neurological Institute, University at Buffalo from 2007 to 2010. The
study was approved by Health Sciences IRB of the University at
Buffalo. Exclusion criteria consisted of patients with seizures
secondary to neoplasm, alcohol, or metabolic illness, poor
compliance with antiepileptic drugs (AEDs), a history of drug
abuse, vagus nerve stimulator (VNS), patients who were unaware
of their seizures in the absence of reliable witness and ﬁnally
patients who did not have follow-up for at least 6 months.
The diagnosis of epilepsy was made by an epileptologist based
on clinical history of recurrent epileptic seizures and supporting
EEG data. Seizure classiﬁcation was conﬁrmed by the same
epileptologist based on prolonged video-EEG monitoring data and
using International League Against Epilepsy (ILAE) criteria. Seizure
frequency was determined by reviewing monthly seizure calen-
dars which were ﬁlled by the patient or their caregivers. All
patients had completed the same questionnaire which included
Epworth Sleepiness Scale (ESS), seizure frequency, and compre-
hensive medical history. The presence of snoring and witnessed
apneas was assessed by history.
Type and frequency of epileptic seizures, as well as previous and
current antiepileptic drug (AED) treatment were reviewed.
Medically refractory epilepsy was deﬁned as any recurrent
complex partial or generalized seizure in the past six months
despite adequate use and compliance with at least two tolerated
and appropriately chosen anticonvulsant medications in the past.
Seizure freedom was deﬁned as lack of recurrence of any complex
partial or generalized seizure in the past six months. Improved
seizure control was deﬁned as reduction of seizure counts by at
least 50% due to therapeutic intervention (AEDs, surgery, or CPAP)
which is an established criteria used in epilepsy clinical trials.25
For the ease of statistical analysis and comparison of seizure
frequencies between groups, we used modiﬁed Engel Criteria for
seizure frequency and assigned a seizure frequency number
between 0 to 12 for each patient visit.26 As per modiﬁed Engel
Criteria we assigned 0 for seizure free and off AEDs, 1 for seizure
free and need for AEDs unknown, 2 for seizure free and requires
AEDs to remain so, 3 for non-disabling simple partial seizures, 4 for
non-disabling nocturnal seizures only, 5 for 1–3 seizures per year,
6 for 4–11 seizures per year, 7 for 1–3 seizures per month, 8 for 1–6
seizures per week, 9 for 1–3 seizures per day, 10 for 4–10 seizures
per day, 11 for >10 seizures per day, and 12 for status epilepticus
without barbiturate coma. By these criteria seizure frequency of 4
or above was assigned as medically refractory and seizure
frequency of 3 or lower was considered as well-controlled.
Patients were routinely referred to have polysomnography
(PSG) if there was clinical suspicion of OSA which included
ESS > 12, snoring, or apneas during sleep observed by bed partner.
Routine diagnostic overnight PSG was performed as previously
described.27 Brieﬂy, sleep state was recorded with four channels of
electro-encephalogram (C3/A2, C4/A1, O2/A1, O1/A2), two chan-
nels of electro-oculogram, and one-channel submental electro-
myogram. Breathing was assessed by monitoring chest and
abdominal movements with piezopneumographs, and nasal and
oral airﬂow using pressure transducers and thermistors. Arterial
oxygen saturation was measured using a pulse oximeter.Respiratory events were scored as obstructive apnea when a
decrease in the airﬂow was 90% or greater for 10 or more seconds,
hypopnea when a decrease in the airﬂow was 50% or greater for 10
or more seconds, associated with either a 4% oxygen desaturation
or an EEG arousal lasting 3 s or longer. The average number of
apneas and hypopneas per hour of sleep (apnea-hypopnea index
(AHI)) was calculated. OSA was rated according to the American
Academy of Sleep Medicine standard guidelines: mild OSA with
AHI of 5–15; moderate OSA with AHI of 16–30; severe OSA with
AHI of more than 30.28 CPAP treatment was initiated for patients
with moderate or severe OSA, or mild OSA and excessive daytime
sleepiness in accordance with ofﬁcial guidelines.29 Compliance
with CPAP treatment was assessed by data download from CPAP
machine and/or clinical interview records.
2.1. Statistical analysis
In statistical regression modeling, the patient population was
split into the medically refractory and medically controlled groups.
We assessed the risk factors contributing to the incidence of sleep
apnea in each of these groups. Wilcoxon signed rank test, student t-
test, and Fisher exact test were used for categorical and continuous
variables as appropriate.
Multiple logistic regression models were used to investigate the
associations of predictor variables with OSA incidence adjusted for
each possible predictor in the model. Signiﬁcance was set at
p < 0.05. Statistical analysis was performed using STATA (Stata-
corp, TX).
3. Results
Total of 312 charts were reviewed. We identiﬁed 197 subjects
who met the inclusion criteria. Reasons for exclusion included
seizures secondary to drug or alcohol abuse, neoplasm, metabolic
causes (n = 9), non-compliance with AEDs (n = 14), VNS treatment
(n = 18), loss to follow-up (n = 25), incomplete sleep/seizure
questionnaire/history (n = 47), new-onset seizure with less than
Table 2
Characteristics of the patients with both epilepsy and OSA.
Well-controlled, N = 17 Refractory, N = 13
Age (year) 54.9  14.4 48.4  9.9
Male 9 (52.9%) 6 (46.2%)
Age at seizure onset (year) 39.5  21.1** 21.6  15.0**
BMI (kg/m2) 28.2  5.6* 35.0  10.3*
Number of AEDs 1.4  0.61* 1.8  0.55*
Monotherapy 12 (70.62%)* 3 (23.1%)*
ESS 5.1  3.9 8.1  5.7
Snore 5 (29.4%)y 9 (69.2%)y
Difﬁculty falling asleep 3 (17.6%) 5 (38.5%)
Difﬁculty staying asleep 10 (58.8%) 6 (46.2%)
Final Seizure frequency 2.0  0.3*** 5.5  2.1***
Daytime sleepiness 6 (35.3%) 4 (30.8%)
HTN 6 (35.3%) 5 (38.4%)
DM 3 (17.7%) 4 (30.8%)
CHF 4 (23.5%) 2 (15.4%)
CAD 2 (11.8%) 2 (15.4%)
Stroke 2 (11.8%) 1 (7.7%)
Values reported are means  standard deviations, with corresponding percentages.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
y p = 0.06.
Seizure frequency based on modiﬁed Engel Criteria.
Table 3
Regression model for patients with well-controlled epilepsy and OSA.
Odd ratio 95% conﬁdence
interval
p-Value
Age 1.06 1.02 1.10 0.005
Male gender 5.12 1.20 21.81 0.027
Difﬁculty staying sleep 5.73 1.43 22.84 0.013
Daytime sleepiness 7.52 1.55 36.59 0.012
Initial seizure frequency 0.19 0.05 0.76 0.019
Table 4
Regression model for patients with refractory epilepsy and OSA.
Odd ratio 95% conﬁdence
interval
p-Value
DM 9.39 1.44 61.2 0.02
Snoring 12.59 2.93 53.91 0.001
P. Li et al. / Seizure 21 (2012) 717–721 719six months on AEDs (n = 1), and death after single visit due to other
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3.1. Characteristics of the patient population
Of the 197 subjects who met the inclusion criteria, 112 (56.9%)
reached seizure freedom at the end of the study without surgical
intervention, and 85 (43.1%) remained medically refractory. Seven
patients who had medically refractory epilepsy underwent surgery
for epilepsy and achieved seizure freedom as a result. The mean
age was 43.6  15.9 (range 19–88), and the age at the onset of ﬁrst
seizure was 23.7  21.5 (range less than 1–77). The duration of follow
up was 2.04  1.28 years (range 0.66–5.11 years). The descriptive
data for both groups are shown in Table 1.
There were no signiﬁcant age or gender differences between
medically refractory or well-controlled epilepsy patients. The
incidence of hypertension, DM, depression/anxiety, congestive
heart failure, coronary artery disease, stroke, or seizure types did
not reach statistical signiﬁcance between the two groups. As
expected, patients with refractory epilepsy were taking more AEDs
compared with those with well-controlled epilepsy (1.88  0.85 vs.
1.38  0.62 respectively, p < 0.001). In patients with either well-
controlled or refractory epilepsy, there were no signiﬁcant differences
regarding the use of AEDs between subjects with OSA and without
OSA, although more refractory patients were on benzodiazepines,
phenytoin or topiramate (p = 0.05, 0.021, <0.0005 respectively) for
their seizure control.
Patients with medically refractory seizures tended to have
higher BMI, younger age of seizure onset, and more symptoms of
sleep disturbance. There was no signiﬁcant difference in OSA
diagnosis between the refractory epilepsy and the seizure-free
group.
3.2. Characteristics of patients with both epilepsy and OSA
Table 2 illustrates the demographic, clinical, and sleep related
characteristics of those who have both epilepsy and OSA. Out of
197 subjects who were included in the study, 56 patients had
ESS > 12 or snoring, 30 of which had conﬁrmed OSA by PSG study.
‘‘epilepsy + OSA’’ patients were older than epilepsy patients
without OSA (age 52.1  12.9 vs. 42.1  16.1, p < 0.002). Seventeen
of them reached seizure freedom at the time of study before CPAPtreatment, while 13 of them were considered having medically
refractory epilepsy according to the criteria. The AHI and O2 nadir
between the two groups were not signiﬁcantly different either (data
not shown). ‘‘refractory epilepsy + OSA’’ patients had their ﬁrst
seizure at a younger age (21.6  15.0 vs. 39.5  21.1, p < 0.01), and
were heavier (BMI 35.0  10.3 vs. 28.2  5.6, p < 0.05) than
‘‘medically controlled epilepsy + OSA’’ patients. Also they had more
snoring and sleep disturbance symptoms but did not reach
signiﬁcance (p = 0.06) due to small sample size of patients.
3.3. Factors associated with OSA
Multiple logistic regression models were conducted to adjust
for the differences in age, gender, BMI, age at ﬁrst seizure,
hypertension, DM, cardiovascular disease, seizure frequency, ESS,
difﬁculty falling sleep, difﬁculty staying sleep, daytime sleepiness,
and snoring. For patients with well-controlled epilepsy (Table 3), it
showed that older age, male gender, difﬁculty staying sleep, and
daytime sleepiness were associated with higher chance for OSA
diagnosis. Lower seizure frequency was associated with lower risk
for OSA. However, in patients with refractory epilepsy, diabetes
and snoring were the predictors of a diagnosis of OSA (Table 4).
3.4. Effect of CPAP treatment for seizure control
Of the 30 patients with both epilepsy and OSA, most suffered
from complex partial seizures with or without secondary generali-
zation (23 out of 30 or 77%). Fourteen were on at least two AEDs.
Fifteen out of the 30 patients with ‘‘OSA + epilepsy’’ were compliant
with CPAP treatment, 9 of which had well-controlled epilepsy and
the other 6 suffered from refractory epilepsy. In CPAP compliant
well-controlled epilepsy + OSA group, any additional beneﬁt of CPAP
for improving their seizure control could not be assessed. The
remaining 6 patients with refractory epilepsy before CPAP treatment
and OSA all showed signiﬁcant improvement in seizures, with 3
patients reached seizure freedom at the end of study. In 4 out of these
6 patients the improvement in seizure frequency was solely due to
the use of CPAP (1.31  0.39 reduced to 0.15  0.15 seizures per
month, p = 0.02). In 2 patients other contributing factors to their seizure
improvement were identiﬁed (i.e. epilepsy surgery and change in AED).
Therefore, 100% of patients with coexisting refractory epilepsy and
OSA, who were compliant with CPAP treatment, showed improved
seizure control.
4. Discussion
Few previous studies have assessed the risk factors for OSA
in an epilepsy population. They showed that these patients with
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frequently male, and sleepier than ‘‘epilepsy only’’ patients.11,12
Our study is the ﬁrst to compare different risk factors for OSA
between well-controlled and refractory epilepsy groups. For
patients with well-controlled epilepsy our study conﬁrms the
above mentioned ﬁndings that older age, male gender, and higher
seizure frequency were predictors of a diagnosis of OSA. In
refractory epilepsy patients with OSA, we found signiﬁcantly
higher BMI, snoring, sleep disturbance symptoms and younger age
of seizure onset compared with patients with coexisting medically
controlled epilepsy and OSA. In addition our patients with
refractory epilepsy had more typical metabolic syndrome associ-
ated with sleep apnea including DM when adjusting for multiple
variables. Therefore the presence of diabetes in refractory epilepsy
subjects warrants further sleep study.
Our ﬁndings suggest a tendency for higher incidence of OSA
compared with the study by Manni et al. (15.2% vs. 10.2%).11 This
difference may be due to different designs of the studies. The
diagnostic method of portable PSG with no EEG recording might
have underestimated the incidence of OSA in their patient
population. Also, exclusion of epilepsy patients with DM and
patients who were previously investigated for a sleep disorder
could have contributed to their lower reported incidence of OSA in
epilepsy patients.11
In this study we excluded the patients with vagus nerve
stimulator due to known effects of VNS on sleep related
breathing30 and difﬁculties with CPAP titration in the presence
of standard VNS on/off cycling mode.31 It will be interesting to
study the incidence of OSA in the subset of epilepsy patients with
VNS.
Despite a recent proposal by the ad hoc Task Force of the ILAE
Commission for deﬁnition of medically refractory epilepsy, there is
still controversy as to the required length of seizure freedom to
determine response to treatment. The task force deﬁned drug
resistant epilepsy as failure to respond to adequate trials of two
tolerated and appropriately chosen AED schedules to achieve
sustained seizure freedom. The length of time required to
determine responsiveness to treatment was deﬁned as seizure-
free for three times pretreatment interseizure interval, or 12
months, whichever is longer.32
In the study by Malow et al.12 which studied sleep disorder in
medically refractory epilepsy patients, the patients had at least one
seizure in the last month and there were 33% of subjects found to
have OSA. We chose to use more clinically relevant criteria for
refractory epilepsy, which was any recurrent complex partial or
generalized seizure in the past six months despite adequate use of
at least two tolerated and appropriately chosen anticonvulsant
medications in the past.
Sleep can inﬂuence seizures and interictal epileptiform
discharges. It has been shown that during non-rapid eye
movement (NREM) sleep seizure activity can be more common
due to neuronal synchronization and recruitment of a critical mass
of neurons to initiate and sustain a seizure.33 One example is the
syndrome of continuous spike-wave activity during slow-wave
sleep which is inhibited during wakefulness and REM sleep.34,35
Desynchronization during REM sleep may restrict the ﬁeld of the
above discharges.35,36 Others have shown that patients with
epilepsy are at higher risk for apnea than the general population,
due to sedentary lifestyle or the effects of antiepileptic therapies on
OSA.12 Sleep fragmentation in OSA which results in increased sleep
stage transitions can facilitate the occurrence of seizures,14,37
whereas epileptic seizures can induce apneas.38 Seizures and
interictal epileptiform spikes are facilitated by lighter stages of
sleep and during sleep–wake transition.39 There is report of direct
effect of CPAP on reducing the interictal spikes and therefore
potential for reducing epileptogenicity.40There have been several studies that showed improvement of
epileptic seizures with treatment of OSA.2,14,15,17,41,42 In these
studies about 40–56% of patients showed improvement in seizure
frequencies independent of their AED changes. Vendrame et al.17 in
a retrospective study showed 28 patients out of 41 subjects with
OSA and epilepsy were CPAP compliant. Sixteen (57%) of CPAP
compliant patients became seizure free compared with 3 of non-
compliant patients. However, Malow et al. in a randomized pilot
trial19 showed no signiﬁcant difference in seizure frequency
reduction in CPAP vs. sham CPAP treated groups. Only 4 out of their
28 epilepsy subjects treated with CPAP became seizure free. The
population of epilepsy patients in their study was severely
refractory (average baseline seizure frequency of 14.7–16.1
month1). The hypoxic effects in this severely refractory epilepsy
population might have been too advanced to be reversed by CPAP
therapy. Also, the patients were only followed for eight weeks after
the initiation of CPAP treatment, which may be too short to see any
effects from the treatment. We have found that all of our patients
with refractory epilepsy and OSA who were compliant with CPAP
showed signiﬁcant improvement in their seizure control. Although
our sample size was small, the results warrant emphasizing CPAP
compliance in medically refractory epilepsy patients with coex-
isting OSA as an adjunctive non-pharmacological means to help
their seizure control.
One of the strengths of our study is the fact that we studied all
patients who were referred to the adult epilepsy center regardless
of their sleep problems. The epilepsy population we studied was
not biased toward any sleep-related problems. Also, to our
knowledge there are no other studies comparing the character-
istics and risk factors in refractory vs. well controlled epilepsy
population who have coexisting OSA.
The limitations of our study include that the patient population
is from a tertiary epilepsy center which may include more patients
with medically refractory epilepsy. Also, by retrospective nature of
this study, not all of the enrolled patients received PSG evaluation.
This may have underestimated the incidence of OSA in our epilepsy
population. In addition due to retrospective study, other possible
confounding factors such as non-compliance with AED use and
inaccurate seizure count cannot be ruled out. Other limitation was
small sample size in CPAP compliant epilepsy + OSA patients.
We need to better identify epilepsy patients who are at higher
risk for OSA since treating OSA with CPAP can improve seizure
control and quality of life. Further prospective studies are needed
to investigate predictors of OSA in an epilepsy population and to
determine the importance of diagnosis and treating OSA in
management of patients with medically refractory epilepsy. This
will give a whole new perspective in treatment of epileptic seizures
before resorting to polypharmacy and invasive surgery.
5. Conclusions
Our ﬁndings support previous studies that show a higher
percentage (15.2%) of OSA in epilepsy patients compared to the
general population (2% for women and 4% for men).43 However, we
did not ﬁnd higher OSA rate in refractory vs. well-controlled
epilepsy patients. The use of CPAP in our refractory epilepsy
patients with OSA signiﬁcantly improved their seizure control.
Patients with refractory epilepsy who have diabetes are more
likely to have OSA. We suggest that in refractory epilepsy patients
with diabetes speciﬁc attention should be focused on further sleep
study tests.
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